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Molecular characterization of Plasmodium falciparum dihydrofolate 
reductase (dhfr) and dihydropteroate synthase (dhps) mutations in 
isolates from eastern Sudan 
 
 
Background 
In Sudan sulfadoxine-pyrimethamine (SP) was the second line antimalarial 
treatment for uncomplicated falciparum malaria till June 2004 when the first 
and second line antimalarial drugs have been switched to Artesunate plus SP 
and Artemether plus lumefanterene, respectively. Treatment failure caused by 
SP resistant P. falciparum has been reported in Khartoum, eastern and 
southern Sudan.  
 
Objectives 
This study aimed at providing baseline information on the distribution of 
Pfdhfr, Pfdhps SP resistance determinant haplotypes to guide future policies 
for malaria treatment in Sudan. 
 
Methods 
PCR and ELISA based technology was used to examine single nucleotide 
polymorphisms in Pfdhfr and Pfdhps genes, known to be associated with SP 
resistance in pretreatment isolates obtained from New Halfa and Kassala 
sites, eastern Sudan during the malaria transmission season of 2005. 
 
Results 
Quintuple mutant parasite at Pfdhfr 51/59/108 and at Pfdhps 437/540 was 
found in New Halfa (2.9%) and in Kassala (5.9%). The frequency of Pfdhfr 
triple mutant haplotype was 2.5% in New Halfa and 4.1% in Kassala. In both 
sites, Pfdhps haplotype harboring (437G/540E) is the most frequent Pfdhps 
mutant haplotype yielding a percentage of 17.7% in New Halfa and 62.5% in 
Kassala.  
 
Conclusions 
In the two study sites effectiveness of SP is expected. Detection of Pfdhfr 
triple, and Pfdhps double mutant haplotypes, in addition to the quintuple 
mutations at Pfdhfr and Pfdhps key positions; in both sites is disturbing, since 
SP is a component of the first line antimalarial drug in Sudan.  
 
 
 
 
 
 
 
 
 
 
